|
Active substance |
Cabozatinib |
|
Holder |
IPSEN Pharma |
|
Status |
Closed |
|
Indication |
Advanced renal cell carcinoma in adults following prior vascular endothelial growth factor (VEGF)- targeted therapy. |
|
Public documents |
|
|
Last update |
16/02/2018 |
Cabometyx®
Last updated on 10/09/2024